Subcommittee weighs HB 554 to broaden insurer coverage for licensed nonopioid pain therapies

The Health, Human Services and Elderly Affairs interim study subcommittee met to consider House Bill 554, legislation intended to expand patient access to licensed, nonopioid pain treatments by clarifying definitions and insurer obligations.

The chair opened the session saying the bill’s purpose is to "increase access to therapies that we know have value," framing the measure as a response to gaps revealed during the opioid crisis and to inconsistent insurer coverage. The bill’s prime sponsor, David Lundgren, was noted as present.

Members focused first on the statutory definition of pain. The committee heard that the International Association for the Study of Pain updated its definition in 2020; the chair and other members proposed inserting "patient centered" into the bill and dropping a separate durational definition of "chronic pain" for this enactment. "If we define pain as patient centered, we probably have done enough for the legislative element of it," the chair said during the discussion.

Why it matters: a narrow durational definition can affect whether insurers pay for services. Members debated whether a strict three‑month cutoff should be in the statute and warned that such a rule can become a rigid gate for coverage; one member argued, "I would remove it," referring to the three‑month durational language.

Scope and modalities: the subcommittee narrowed eligible services to interventions provided by licensed practitioners—examples discussed included chiropractic care, acupuncture, licensed massage, and behavioral therapies such as cognitive behavioral therapy. The draft discussed in the meeting excluded, for now, many movement or community modalities (yoga, Qigong, Tai Chi) unless those therapies develop recognized credentialing.

Use limits and cost controls: members reviewed utilization proposals from earlier drafts. An original draft had listed up to 20 visits per listed modality; insurers flagged that as costly and susceptible to cumulative overuse. The working compromise discussed was limiting access to a smaller number of visits per modality (the chair described 12 as a negotiated compromise) while allowing multimodal, coordinated care so therapies can be used together when clinically appropriate.

Insurer role and prior authorization lessons: multiple members described insurers as the practical "gatekeepers" for coverage, pointing to prior authorization rules as a barrier to timely access. The subcommittee discussed using an ad‑hoc stakeholder group—drawing insurers, providers and patient advocates—to agree on evidence thresholds, provider credential requirements and implementation details. The chair said that earlier stakeholder negotiation had helped the bill gain broader buy‑in and suggested repeating that approach.

Draft management and next steps: committee members asked for a consolidated, unredacted draft in ordinary OLS format (statute text with struck and new language clearly indicated). The chair agreed to circulate a cleaned ('all black') version for review. Members also discussed timing: an interim study report is due by Oct. 25 and a full committee work session was tentatively scheduled for Oct. 8–9. The chair urged filing the bill in a manner that allows additional stakeholder work and said a Senate vehicle may be considered for timing advantages.

What was not decided: the subcommittee did not take a formal final vote on HB 554 language; it endorsed a path forward—stakeholder drafting, circulation of a clean draft, and at least one follow‑up meeting—without imposing final statutory text. The chair emphasized that insurers must be part of the process if the proposal is to be viable.

The subcommittee left the record with clear next steps: the chair will circulate a consolidated draft for comment, reconvene (or allow members to comment in writing in accordance with open‑meeting rules), and prepare an interim study report for the October deadline.